

# CITATION REPORT

List of articles citing

Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine

DOI: 10.1007/s40262-017-0566-9

Clinical Pharmacokinetics, 2018, 57, 379-392.

**Source:** <https://exaly.com/paper-pdf/84237562/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate. <i>Bioanalysis</i> , <b>2018</b> , 10, 1229-1248	2.1	11
10	Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia. <i>PLoS ONE</i> , <b>2019</b> , 14, e0204540	3.7	5
9	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. <i>Pediatric Blood and Cancer</i> , <b>2019</b> , 66, e27900	3	2
8	Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 123-135	6.2	1
7	Mitotic Poisons in Research and Medicine. <i>Molecules</i> , <b>2020</b> , 25,	4.8	13
6	Potential Drug-Drug Interactions with Combination Volasertib+ Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, 2214-2224	3.5	2
5	RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. <i>FASEB Journal</i> , <b>2021</b> , 35, e21476	0.9	2
4	PLK1 Inhibition Sensitizes Breast Cancer Cells to Radiation via Suppressing Autophagy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 1234-1247	4	3
3	Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351. <i>Journal of Controlled Release</i> , <b>2021</b> , 338, 244-252	11.7	2
2	Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia.		
1	PLK1 inhibition-based combination therapies for cancer management.. <i>Translational Oncology</i> , <b>2021</b> , 16, 101332	4.9	4